Zhang Rui, Wang Jingjing, Wu Chenguang, Wang Lifan, Liu Peng, Li Ping
Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Shunyi Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing, China.
Heliyon. 2025 Jan 2;11(1):e41620. doi: 10.1016/j.heliyon.2024.e41620. eCollection 2025 Jan 15.
Chronic kidney disease (CKD) is by far the most prevalent disease in the world and is now a major global public health problem because of the increase in diabetes, hypertension and obesity. Traditional biomarkers of kidney function lack sensitivity and specificity for early detection and monitoring of CKD progression, necessitating more sensitive biomarkers for early diagnostic intervention. Dyslipidemia is a hallmark of CKD. Advancements in mass spectrometry (MS)-based lipidomics platforms have facilitated comprehensive analysis of lipids in biological samples and have revealed changes in the lipidome that are associated with metabolic disorders, which can be used as new biomarkers for kidney diseases. It is also critical for the discovery of new therapeutic targets and drugs. In this article, we focus on lipids in CKD, lipidomics methodologies and their applications in CKD. Additionally, we introduce novel biomarkers identified through lipidomics approaches and natural products derived from lipidomics for the treatment of CKD. We believe that our study makes a significant contribution to literature by demonstrating that natural products can improve CKD from a lipidomic perspective.
慢性肾脏病（CKD）是目前世界上最普遍的疾病，由于糖尿病、高血压和肥胖症的增加，它现在已成为一个主要的全球公共卫生问题。传统的肾功能生物标志物在早期检测和监测CKD进展方面缺乏敏感性和特异性，因此需要更敏感的生物标志物用于早期诊断干预。血脂异常是CKD的一个标志。基于质谱（MS）的脂质组学平台的进步促进了对生物样品中脂质的全面分析，并揭示了与代谢紊乱相关的脂质组变化，这些变化可用作肾脏疾病的新生物标志物。这对于发现新的治疗靶点和药物也至关重要。在本文中，我们重点关注CKD中的脂质、脂质组学方法及其在CKD中的应用。此外，我们介绍了通过脂质组学方法鉴定的新型生物标志物以及源自脂质组学用于治疗CKD的天然产物。我们相信，我们的研究通过证明天然产物可以从脂质组学角度改善CKD，为文献做出了重大贡献。
